![<?echo $_SERVER['SERVER_NAME'];?>](/template/twentyseventeen/skin/images/header.jpg)
Founded in 1981, Shanghai Kehua Bioengineering Co., Ltd. is the largest medical diagnostics industrial base in China. Kehua Biotech is listed on the Shenzhen Stock Exchange and has a complete industrial chain in the field of medical diagnostics. It covers in vitro diagnostic reagents, medical testing instruments, and vacuum blood collection systems.
At present, from June to August, Kehua Bioreal has achieved operating revenue of 462,210,200 yuan, a year-on-year increase of 19.17%; total profit of 14,197.16 million yuan, an increase of 4.35%. The increase in its operating income and total profit was mainly due to the steady growth of the in-vitro diagnostic reagent business and the unexpected increase in medical instrument business.
During this period, the sales revenue of Kehua's biological diagnostic reagent business was 21,193.36 million yuan, a year-on-year increase of 13.77% and a gross margin of 76.77%. Although the decline in export business led to a drop in the number of immunological reagents, the business of biochemical reagents and nucleic acid reagents has grown substantially. In the field of medical equipment business, there was an unexpected increase in growth, which was a year-on-year increase of 23.05%. No matter if it is an agent instrument or a self-produced instrument, there has been a significant increase over the same period last year.
This is also closely related to the long-term adherence to scientific innovation by Kehua Biotechnology. In the first half of this year, Kehua Biotechnology has obtained five new product registration certificates, one invention patent and one utility model patent. These new products have also become a powerful driving force for company development.
At present, from June to August, Kehua Bioreal has achieved operating revenue of 462,210,200 yuan, a year-on-year increase of 19.17%; total profit of 14,197.16 million yuan, an increase of 4.35%. The increase in its operating income and total profit was mainly due to the steady growth of the in-vitro diagnostic reagent business and the unexpected increase in medical instrument business.
During this period, the sales revenue of Kehua's biological diagnostic reagent business was 21,193.36 million yuan, a year-on-year increase of 13.77% and a gross margin of 76.77%. Although the decline in export business led to a drop in the number of immunological reagents, the business of biochemical reagents and nucleic acid reagents has grown substantially. In the field of medical equipment business, there was an unexpected increase in growth, which was a year-on-year increase of 23.05%. No matter if it is an agent instrument or a self-produced instrument, there has been a significant increase over the same period last year.
This is also closely related to the long-term adherence to scientific innovation by Kehua Biotechnology. In the first half of this year, Kehua Biotechnology has obtained five new product registration certificates, one invention patent and one utility model patent. These new products have also become a powerful driving force for company development.
Nantong Weizhuo Environmental Protection Equipment Co.,Ltd , https://www.natongcwz.com